Insulin Resistance & Metabolic Health
Insulin resistance — reduced cellular response to insulin — is the central driver of type 2 diabetes and a major contributor to cardiovascular risk, described by Reaven's landmark 1988 Banting Lecture. It develops years before glucose becomes abnormal, and population data suggest only about 1 in 8 American adults meets criteria for optimal metabolic health, making early measurement one of the highest-yield actions in preventive medicine.
Written/Reviewed by: Dr. Michael Ellis, DO — Medical Director
Scientific/Technical contribution: John Campetella
Last medical review: June 2026
What the science established
Reaven's syndrome-X framework connected insulin resistance to hypertension, dyslipidemia and cardiovascular disease decades before it was mainstream. Modern cohort data confirm the downstream consequences, and NHANES-based analysis (Araújo 2019) found only ~12% of US adults achieve optimal levels across five metabolic-health criteria.
Why early testing matters
Fasting insulin rises long before fasting glucose or HbA1c leaves the normal range, because the pancreas compensates by secreting more insulin. Measuring fasting insulin (and derived indices such as HOMA-IR) alongside post-meal glucose patterns surfaces dysfunction in the compensated phase — when lifestyle intervention is most effective.
The role of CGM
Continuous glucose monitoring shows real-world glycemic response to actual meals, exercise, stress and sleep. International consensus (Battelino 2019) defines time-in-range and variability targets, giving CGM data a rigorous interpretive framework beyond wellness anecdotes.
Limitations
Fasting insulin assays are not fully standardized between labs, HOMA-IR is a surrogate rather than a clamp measurement, and CGM time-in-range targets were developed primarily for diabetes populations. Interpretation in metabolically healthy adults requires clinical context — which is why our results are physician-reviewed.
The Integrated Wellness approach
We combine fasting insulin, lipid fractionation, inflammatory markers and 2+ weeks of CGM data inside the Matrix Engine, read against genetics, body composition and recovery trends — then verify protocol response by retesting rather than by feel.
A = consistent RCT/meta-analytic · B = strong observational/mixed · C = limited · Emerging = active research
- Reaven GM (1988). Banting Lecture: Role of insulin resistance in human disease. Diabetes.
- Araújo J, Cai J, Stevens J (2019). Prevalence of optimal metabolic health in American adults (NHANES 2009–2016). Metabolic Syndrome and Related Disorders.
- Battelino T, et al. (2019). Clinical targets for continuous glucose monitoring data interpretation. Diabetes Care.